Back to the main directory
EarningsReview / Equity
- In The Waiting Room - 3Q18 Prep by BNP Paribas Exane
- ALK: To Live and Die in CA: Shifting Focus to Digesting the Merger by Raymond James
- Alligator Bioscience (Buy, TP: SEK42.00) - Worth waiting for by DnB Markets
- Swedish Orphan Biovitrum (Buy, TP: SEK360.00) - We expect continued strong growth by DnB Markets
- Ahlsell AB (Buy, TP: SEK70.00) - Delivery not reflected in shares by DnB Markets
- TBBK: Reiterate Strong Buy; Thesis/Outlook Unchanged Following Strong Quarter by Raymond James
- Swedish Orphan Biovitrum (Buy, TP: SEK360.00) - We expect continued strong growth by DnB Markets
- EQR: Maintaining Underperform Amid Sluggish Growth, 2019 Supply Hurdles by Raymond James
- Pareto Bank (Buy, TP: NOK50.00) - Solid quarter despite lower activity by DnB Markets
- Sparebank 1 Østlandet (Buy, TP: NOK100.00) - Solid growth momentum by DnB Markets
- Execution and oil leverage paying off by BNP Paribas Exane
- FR: We're Watching Trade, the Consumer & Selective Retailers, but So Far, So Good by Raymond James
- LKFN: Maintain Market Perform on Valuation Following Solid 3Q Results by Raymond James
- ROP: Roper Does It Again and Stays on Track for Impressive 2018 by Raymond James
- NR: Newpark Continues Progression on Strategic Vision by Raymond James
- SBCF: 3Q18 Follow-Up: Fundamentals Remain Strong; Maintain Market Perform by Raymond James
- UHS: Behavioral Acceleration Still Elusive; Trimming Out Quarter Estimates by Raymond James
- PSXP: 3Q Recap: Another Strong Qtr, More Growth Coming; Outperform, TP to $62 by Raymond James
- ZBH: 3Q Fine, Although Speed Bumps Still Ahead, More Good News Than Bad by Raymond James
- Sparebank1 Nord-Norge (Buy, TP: NOK76.00) - Utilising profitable growth window by DnB Markets
- Weekly NAV update by DnB Markets
- Short-term pain for long-term gain by BNP Paribas Exane
- Medistim (Buy, TP: NOK81.00) - Mixed report, expanding base by DnB Markets
- Schibsted (Sell, TP: NOK250.00) - It’s harvest time by DnB Markets
- ZION: Raising EPS Estimates for Capital Actions by Raymond James